semaglutide ban 2025 How compounders plan to continue making GLP-1s Novo Nordisk's semaglutide shortage officially

In the non-diabetes cohort, participants receiving the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks a figure that substantially exceeds weight loss outcomes reported with currently approved agents at comparable timepoints

Finally, no observed differences were seen between the two groups (20)

Mounjaros dual GLP-1/GIP receptor agonist mechanism also delivers about 2.0-2.5% A1c reduction versus Victozas 1.0-1.5%

Bell LN, Cai L, Johnstone BH, Traktuev DO, March KL, Considine RV

Toxicol Environ Health Sci

Your healthcare team can help you find a balance between managing your health and protecting your baby